The proposed scoping review will be conducted in accordance with the Joanna Briggs Institute methodology for scoping reviews.44
Eligibility criteria
Participants
Due to the highly specialized area of practice in which cancer SMG are implemented, eligible studies will be limited to those in which the implementation strategies target specialized and/or advanced practice oncology nurses, as defined above. Nursing designations for specialized and advanced oncology nurses will include registered nurses (RNs), licensed practical nurses (LPNs), registered practical nurses (RPNs), or advanced practice nurses (APNs). APNs will be considered an umbrella term that includes clinical nurse specialists (CNS), nurse practitioners (NPs), and those working in generically titled advanced practice nursing roles.31 45 Studies involving other oncology care providers will be considered if specialized or advanced oncology nurses are included within the population and findings for nurses are reported separately. Studies involving nursing students or unregulated care providers alone will be excluded. Given that SMG and implementation strategies are likely to differ between adult and pediatric patients, this review will consider studies involving adult oncology populations only.
Concept
Eligible studies must report one or both of the following concepts: 1) implementation strategies and strategy components that have been used to enhance the adoption, implementation, and/or sustainability of cancer SMG, and/or 2) factors influencing the implementation of cancer SMG, understood broadly as the influences on specialized and advanced oncology nurses’ behaviour32 related to the adoption, implementation, and sustainability of SMG. These complex factors may act as enablers or barriers to implementation.46
Studies involving the implementation of SMG for the management of any cancer-related symptom will be included, such as: anxiety, depression, constipation, diarrhea, dyspnea, fatigue, fever, hand-foot syndrome, loss of appetite, nausea, vomiting, oral mucositis, pain, sexual and sleep disturbances, urinary symptoms, neuropathy, skin reactions, lymphedema, and more.12–14 For the purpose of this review, the definition of SMG will include both explicit clinical practice guidelines providing patient care recommendations based on a systematic evidence synthesis and assessment of benefits/harms,47 and evidence-based care protocols, bundles, pathways, and/or checklists. These terms, which are often used interchangeably in the literature,48 describe local approaches to evidence-informed care delivery through the translation of general guideline recommendations into a specific care plan or set of procedures followed by healthcare providers.49 50
Context
Only studies conducted within the context of cancer-specific outpatient settings will be eligible for inclusion. Eligible settings will include outpatient cancer, symptom management and/or apheresis clinics; chemotherapy suites; community-based chemotherapy infusion centers; ambulatory cancer services delivered within or outside of hospitals; medical day care/transfusion units; day hospitals; and cancer specific urgent care settings where care for adult patients with any form of cancer is provided. Studies will be excluded if they take place within institutionalized settings (e.g., inpatient hospital units, emergency departments, long-term care) or non-cancer specific outpatient settings (e.g., public health, primary care, home/community care). No geographic restrictions will be applied.
Types of sources
Published and unpublished primary studies, quality improvement projects, or reports from the grey literature of any design will be eligible for inclusion, including quantitative, qualitative, and mixed methods studies. Reviews, conference abstracts, and editorials/position papers alone will be excluded as they are unlikely to include sufficient detail regarding the components of implementation strategies.
Search strategy
The search strategy will aim to locate both published and unpublished primary studies and grey literature sources. The electronic databases CINAHL (EBSCO), Embase (Ovid), Emcare (Ovid), and MEDLINE(R) (Ovid) will be searched. An initial limited search of CINAHL was performed. Index terms of relevant articles were used to refine the full search strategy for the CINAHL database (Table 1), which was then adapted to each of the remaining databases. A health sciences research librarian provided guidance on the development of the search strategy. Targeted searches of journals of particular relevance to the topic, including Implementation Science, Journal of Pain and Symptom Management, Canadian Oncology Nursing Journal, Clinical Journal of Oncology Nursing, Cancer Nursing, Oncology Nursing Forum, and European Journal of Oncology Nursing will be performed. The reference lists of included articles and systematic, scoping or literature reviews identified during the search will also be screened for eligible studies.
Table 1
CINAHL (EBSCO) Search Strategy
Search
|
Query
|
#1
|
(MH “Oncologic Nursing+”) OR TX [(nurs* OR RN OR RPN OR LPN) N5 (oncolog* OR cancer)] OR TX [(nurs* OR APN OR CNS OR NP) N5 (oncolog* OR cancer)]
|
#2
|
(MH “Diffusion of Innovation”) OR (MH “Implementation Science”) OR (MH “Professional Compliance”) OR TX (“implementation strateg*”) OR TX (“knowledge translation”) OR TX (adopt* OR uptake OR implement* OR utiliz* OR integrat* OR sustain*) OR TX (barrier* OR facilitat*)
|
#3
|
(MH “Practice Guidelines”) OR (MH “Guideline Adherence”) OR (MH “Nursing Practice, Evidence-Based+”) OR (MH Nursing Protocols+) OR TX (guideline*) OR TX (evidence-informed practice OR evidence-informed nursing) OR TX [(evidence based OR evidence informed) N2 (protocol* OR bundle* OR pathway* OR checklist* OR guideline*)]
|
#4
|
#1 AND #2 AND #3
|
Limits: Publication date 2000 to present; English language
|
Due to resource limitations, only articles published in English will be considered for inclusion. Given that efforts to promote comprehensive cancer symptom management through standardized screening tools, patient-reported outcome measures, and the establishment of evidence-based guidelines have primarily occurred within the last 15 years,25 limits will also be placed on the year of publication. Only articles published from the year 2000 to present will be included, as relevant studies are unlikely to exist before this time.
The OpenGrey and ProQuest Dissertations and Theses Global (ProQuest) databases will be used to locate grey literature sources, including theses, dissertations, reports, and quality improvement articles. Websites of relevant nursing organizations and publications, including the Canadian Association of Nurses in Oncology (CANO), Oncology Nursing Society (ONS), and International Society of Nurses in Cancer Care will be searched. Conference proceedings for the CANO Annual Conference, ONS Congress, and International Conference on Cancer Nursing will be screened. Given resource limitations, this targeted screening will be limited to conference proceedings from the last five years. Authors of potentially relevant conference abstracts will be contacted in an attempt to locate full published or unpublished reports, as available.
Study selection
All citations identified in the search will be imported into Covidence (Veritas Health Innovation, Melbourne, Australia) and duplicates will be removed. Two independent reviewers will perform all levels of screening, with any conflicts resolved through discussion or with the input of a third reviewer. Following a pilot test, titles and abstracts of imported citations will be screened against eligibility criteria. Potentially relevant papers will then be retrieved in full and assessed in detail according to established inclusion criteria. Reasons for exclusion of full-text papers will be recorded and reported in the scoping review. The results of the search will be reported in full and presented in a Preferred Reporting Items for Systematic Reviews and Meta-analyses for Scoping Reviews (PRISMA-ScR) flow diagram.51
Data extraction
Data will be extracted in duplicate by two independent reviewers using a standardized data extraction form (Table 2). Any disagreements will be resolved through discussion or with input from a third reviewer. The data extraction tool will be piloted by the review team and revised as necessary during the process of data extraction, and any modifications will be reported in the scoping review. General characteristics of included studies will be collected, including study design, objective(s), and the country in which the study was conducted. Within population, the type of oncology nursing role will be identified (e.g., RN, NP) in an effort to determine whether implementation strategies and factors influencing implementation differ between specialized and advanced oncology nurses. Where reported, nurses’ educational backgrounds, oncology specific training, and years of experience will also be extracted as these factors have previously been associated with nurses’ use of SMG.21 Within context, a description of the outpatient oncology practice setting (e.g., day hospital, clinic), type of setting (e.g., academic, rural, urban), patient population served (e.g., cancer type), services provided (e.g., systemic therapy, pain and symptom management), and size of outpatient setting (e.g., number of patients seen, staff size) will be extracted. A description of the evidence being implemented will also be collected, including the source(s) of the guideline, bundle, protocol, pathway, and/or checklist being used and the target cancer symptom(s).
Table 2
Data Extraction Instrument
Part A: Study Characteristics
|
Study design or type of grey literature
|
|
Purpose/objectives
|
|
Country
|
|
Part B: Population
|
Type of oncology nursing role(s) (e.g., RN, NP)
|
|
Educational background, oncology specific training, and years of experience
|
|
Sample size
|
|
Part C: Context
|
Cancer-specific outpatient setting
|
|
Type and size of setting
|
|
Patient population served and services provided
|
|
Part D: Description of Evidence for Implementation
|
Type and source of evidence for implementation (e.g., guideline, pathway)
|
|
Symptom(s) targeted
|
|
Part E: Implementation Strategies & Outcomes
|
Name of implementation strategy or combination of strategies used
|
|
Actor(s): Who delivered the strategy?
|
|
Action(s): Steps and processes used
|
|
Target(s): To whom and what were the actions directed toward?
|
|
Temporality: Phase or timing of the intervention
|
|
Dose: Frequency and intensity
|
|
Justification: Implementation model, theory, or framework
|
|
Types of outcomes reported (i.e., implementation, service, client)
|
|
Measurement tools and methods of data analysis
|
|
Part F: Factors Influencing Implementation
|
CFIR Domain
|
Facilitators
|
Barriers
|
Intervention characteristics
|
|
|
Inner setting
|
|
|
Outer setting
|
|
|
Characteristics of individuals
|
|
|
Implementation process
|
|
|
Additional notes:
|
Proctor and colleagues34 propose seven components of implementation strategies, namely actors, actions, targets, temporality, dose, justifications, and outcomes, that should be specified within an implementation research study or practice initiative. These categories will therefore be used to extract implementation strategy components. The actor refers to the individual(s) responsible for delivering the strategy, while actions are the steps or processes of implementation. Targets describe who and/or what the actions are directed toward (e.g., known evidence gap or barrier to implementation). Temporality relates to intervention timing, while dose considers intervention frequency and intensity. Justification refers to the theoretical rationale and/or research evidence supporting an implementation initiative. In line with a scoping review approach,44 outcome data will not be collected. However, the types of implementation outcomes (e.g., acceptability, feasibility, cost), service outcomes (e.g., effectiveness, patient-centredness), and client outcomes (e.g., symptomatology)33 reported will be extracted alongside the measurement tools and methods of data analysis used within each of the included studies.
A variety of determinant frameworks exist to identify facilitators and barriers to implementation of an evidence-informed intervention or practice.46 The Consolidated Framework for Implementation Research (CFIR) by Damschroder and colleagues is a comprehensive determinants framework that supports exploration of complex factors influencing implementation. CFIR contains 39 constructs within five domains: intervention characteristics (e.g., complexity, adaptability), outer setting (e.g., patient needs), inner setting (e.g., culture, resources), characteristics of individuals (e.g., knowledge, beliefs), and implementation process (e.g., planning, engaging).42 These domains will be used to guide data extraction of reported facilitators and barriers to SMG adoption, implementation, and sustainability among outpatient oncology nurses. Authors will be contacted to request missing or additional data, where required.
Data analysis and presentation
A descriptive approach to data analysis will be taken, with results presented using diagrams, tables, and narrative summary. A table of included studies will be provided to display study characteristics, as described above. Implementation strategies will be categorized using the ERIC taxonomy35 and frequency counts will be presented to illustrate which implementation strategies or combinations of strategies have been used to enhance the adoption, implementation, and sustainability of cancer SMG. Implementation strategies used in more than one source will be mapped according to their corresponding study designs, settings, and outcome measurements to inform future research in this area, including whether there is sufficient evidence to conduct a systematic review of intervention effectiveness. Barriers and facilitators to SMG adoption, implementation, and sustainability will be analyzed and described according to the CFIR domains and constructs, as applicable.42 Factors influencing SMG implementation will be summarized and presented in a conceptual model consistent with the CFIR structure.
Ethics and dissemination
Human participants will not be involved in the proposed scoping review of published and grey literature sources; therefore, research ethics board approval is not required. Planned knowledge translation activities include a presentation at a national conference to a professional oncology nursing audience, a peer-reviewed journal publication, and academic social media platforms. Dissemination of scoping review findings within local oncology nursing and patient networks will also take place to gain input on recommendations for practice, policy, and research.